Physicians

Chief, Neuropathology and Surgical Pathology
Director, Anatomic Pathology Services
Director, Brain Tumor Center Tissue Bank

Department / Division
Pathology / Pathology Clinical Services

Address
DUMC 3712
Durham, NC 27710

Appointment Telephone
919-684-2533

Office Telephone
919-684-6940

Fax Telephone
919-681-7634

Training

• MD, Medical College of Georgia School of Medicine, 1982

Residency

• Anatomic Pathology, Duke University Medical Center, 1983-1985
• Neuropathology, Duke University Medical Center, 1985-1987

Clinical Interests
Surgical and autopsy pathology of the brain, spinal cord, and their coverings, muscle, and nerve. Call 919-684-3648 for nerve-submission protocols.

Research Interests
Brain tumors are diagnosed in more than 20,000 Americans annually. The most malignant neoplasm, glioblastoma, is also the most common. Similarly, brain tumors constitute the second most common neoplasm in children of which the medulloblastoma is the most common. My research is dedicated to bringing molecular advances involved in the etiology, pathogenesis, and treatment of brain tumors from the bench to clinical application. My primary interest is in finding markers of prognostic and therapeutic significance in medulloblastoma and adult gliomas. The recent identification of mutations of the IDH1 and IHD2 genes as markers of glioblastomas with good prognosis is now online as a diagnostic test. Amplification of oncogenes, particularly EGFR, MYCC, and MYCN and losses of genetic material that may include tumor suppressors at loci such as 10q23, 9p21, 1p, 19q, and 6q are being analyzed in adult and childhood brain tumors to identify unusually aggressive neoplasms. We have developed assays for MGMT that allow the identification of high grade gliomas that may respond to alkylating chemotherapy. We have also developed assays to characterize the subsets of medulloblastomas and ependymomas. We are currently working to identify the therapeutic and prognostic significance of cells found in many gliomas that exhibit features of stem cells.

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.

Representative Publications
Jin, G; Reitman, ZJ; Duncan, CG; Spasojevic, I; Gooden, DM; Rasheed, BA; Yang, R; Lopez, GY; He, Y; McLendon, RE; Bigner, DD; Yan, H. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Research. 2013;73:496-501. (2013) Abstract

Duong, LM; McCarthy, BJ; McLendon, RE; Dolecek, TA; Kruchko, C; Douglas, LL; Ajani, UA. Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004-2007. Cancer. 2012;118:4220-4227. (2012) Abstract

Guo, C; Chang, CC; Wortham, M; Chen, LH; Kernagis, DN; Qin, X; Cho, YW; Chi, JT; Grant, GA; McLendon, RE; Yan, H; Ge, K; Papadopoulos, N; Bigner, DD; He, Y. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proceedings of the National Academy of Sciences of USA. 2012;109:17603-17608. (2012) Abstract

Jiao, Y; Killela, PJ; Reitman, ZJ; Rasheed, AB; Heaphy, CM; de Wilde, RF; Rodriguez, FJ; Rosemberg, S; Oba-Shinjo, SM; Nagahashi Marie, SK; Bettegowda, C; Agrawal, N; Lipp, E; Pirozzi, C; Lopez, G; He, Y; Friedman, H; Friedman, AH; Riggins, GJ; Holdhoff, M; Burger, P; McLendon, R; Bigner, DD; Vogelstein, B; Meeker, AK; Kinzler, KW; Papadopoulos, N; Diaz, LA; Yan, H. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:709-722. (2012) Abstract

Lathia, JD; Li, M; Hall, PE; Gallagher, J; Hale, JS; Wu, Q; Venere, M; Levy, E; Rani, MR; Huang, P; Bae, E; Selfridge, J; Cheng, L; Guvenc, H; McLendon, RE; Nakano, I; Sloan, AE; Phillips, HS; Lai, A; Gladson, CL; Bredel, M; Bao, S; Hjelmeland, AB; Rich, JN. Laminin alpha 2 enables glioblastoma stem cell growth. Annals of Neurology. 2012;72:766-778. (2012) Abstract

Lin, N; Di, C; Bortoff, K; Fu, J; Truszkowski, P; Killela, P; Duncan, C; McLendon, R; Bigner, D; Gregory, S; Adamson, DC. Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. Molecular Cancer Research. 2012;10:208-217. (2012) Abstract

Northcott, PA; Shih, DJ; Peacock, J; Garzia, L; Morrissy, AS; Zichner, T; Stütz, AM; Korshunov, A; Reimand, J; Schumacher, SE; Beroukhim, R; Ellison, DW; Marshall, CR; Lionel, AC; Mack, S; Dubuc, A; Yao, Y; Ramaswamy, V; Luu, B; Rolider, A; Cavalli, FM; Wang, X; Remke, M; Wu, X; Chiu, RY; Chu, A; Chuah, E; Corbett, RD; Hoad, GR; Jackman, SD; Li, Y; Lo, A; Mungall, KL; Nip, KM; Qian, JQ; Raymond, AG; Thiessen, NT; Varhol, RJ; Birol, I; Moore, RA; Mungall, AJ; Holt, R; Kawauchi, D; Roussel, MF; Kool, M; Jones, DT; Witt, H; Fernandez-L, A; Kenney, AM; Wechsler-Reya, RJ; Dirks, P; Aviv, T; Grajkowska, WA; Perek-Polnik, M; Haberler, CC; Delattre, O; Reynaud, SS; Doz, FF; Pernet-Fattet, SS; Cho, BK; Kim, SK; Wang, KC; Scheurlen, W; Eberhart, CG; Fèvre-Montange, M; Jouvet, A; Pollack, IF; Fan, X;. . . Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488:49-56. (2012) Abstract

Pei, Y; Moore, CE; Wang, J; Tewari, AK; Eroshkin, A; Cho, YJ; Witt, H; Korshunov, A; Read, TA; Sun, JL; Schmitt, EM; Miller, CR; Buckley, AF; McLendon, RE; Westbrook, TF; Northcott, PA; Taylor, MD; Pfister, SM; Febbo, PG; Wechsler-Reya, RJ. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012;21:155-167. (2012) Abstract

Zalutsky, MR; Boskovitz, A; Kuan, CT; Pegram, CN; Ayriss, J; Wikstrand, CJ; Buckley, AF; Lipp, ES; Herndon, JE; McLendon, RE; Bigner, DD. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nuclear Medicine and Biology. 2012;39:23-34. (2012) Abstract

Bettegowda, C; Agrawal, N; Jiao, Y; Sausen, M; Wood, LD; Hruban, RH; Rodriguez, FJ; Cahill, DP; McLendon, R; Riggins, G; Velculescu, VE; Oba-Shinjo, SM; Marie, SK; Vogelstein, B; Bigner, D; Yan, H; Papadopoulos, N; Kinzler, KW. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333:1453-1455. (2011) Abstract

Eyler, CE; Wu, Q; Yan, K; MacSwords, JM; Chandler-Militello, D; Misuraca, KL; Lathia, JD; Forrester, MT; Lee, J; Stamler, JS; Goldman, SA; Bredel, M; McLendon, RE; Sloan, AE; Hjelmeland, AB; Rich, JN. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011;146:53-66. (2011) Abstract

Guryanova, OA; Wu, Q; Cheng, L; Lathia, JD; Huang, Z; Yang, J; MacSwords, J; Eyler, CE; McLendon, RE; Heddleston, JM; Shou, W; Hambardzumyan, D; Lee, J; Hjelmeland, AB; Sloan, AE; Bredel, M; Stark, GR; Rich, JN; Bao, S. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011;19:498-511. (2011) Abstract

Heaphy, CM; de Wilde, RF; Jiao, Y; Klein, AP; Edil, BH; Shi, C; Bettegowda, C; Rodriguez, FJ; Eberhart, CG; Hebbar, S; Offerhaus, GJ; McLendon, R; Rasheed, BA; He, Y; Yan, H; Bigner, DD; Oba-Shinjo, SM; Marie, SK; Riggins, GJ; Kinzler, KW; Vogelstein, B; Hruban, RH; Maitra, A; Papadopoulos, N; Meeker, AK. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333:425. (2011) Abstract

Hjelmeland, AB; Wu, Q; Heddleston, JM; Choudhary, GS; MacSwords, J; Lathia, JD; McLendon, R; Lindner, D; Sloan, A; Rich, JN. Acidic stress promotes a glioma stem cell phenotype. Cell Death and Differentiation. 2011;18:829-840. (2011) Abstract

Lathia, JD; Gallagher, J; Myers, JT; Li, M; Vasanji, A; McLendon, RE; Hjelmeland, AB; Huang, AY; Rich, JN. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One. 2011;6:e24807. (2011) Abstract

Lathia, JD; Hitomi, M; Gallagher, J; Gadani, SP; Adkins, J; Vasanji, A; Liu, L; Eyler, CE; Heddleston, JM; Wu, Q; Minhas, S; Soeda, A; Hoeppner, DJ; Ravin, R; McKay, RD; McLendon, RE; Corbeil, D; Chenn, A; Hjelmeland, AB; Park, DM; Rich, JN. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death and Disease. 2011;2:e200. (2011) Abstract

McLendon, RE; Adekunle, A; Rajaram, V; Koçak, M; Blaney, SM. Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. Archives of Pathology and Laboratory Medicine. 2011;135:984-993. (2011) Abstract

McLendon, RE; Rich, JN. Glioblastoma Stem Cells: A Neuropathologist's View. Journal of Oncology. 2011;2011:397195. (2011) Abstract

Mitchell, DA; Cui, X; Schmittling, RJ; Sanchez-Perez, L; Snyder, DJ; Congdon, KL; Archer, GE; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Reardon, DA; Vredenburgh, JJ; Bigner, DD; Sampson, JH. Monoclonal antibody blockade of IL-2 receptor ¿ during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011;118:3003-3012. (2011) Abstract

Parsons, DW; Li, M; Zhang, X; Jones, S; Leary, RJ; Lin, JC; Boca, SM; Carter, H; Samayoa, J; Bettegowda, C; Gallia, GL; Jallo, GI; Binder, ZA; Nikolsky, Y; Hartigan, J; Smith, DR; Gerhard, DS; Fults, DW; VandenBerg, S; Berger, MS; Marie, SK; Shinjo, SM; Clara, C; Phillips, PC; Minturn, JE; Biegel, JA; Judkins, AR; Resnick, AC; Storm, PB; Curran, T; He, Y; Rasheed, BA; Friedman, HS; Keir, ST; McLendon, R; Northcott, PA; Taylor, MD; Burger, PC; Riggins, GJ; Karchin, R; Parmigiani, G; Bigner, DD; Yan, H; Papadopoulos, N; Vogelstein, B; Kinzler, KW; Velculescu, VE. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331:435-439. (2011) Abstract

Sampson, JH; Aldape, KD; Archer, GE; Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gilbert, MR; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sawaya, R; Schmittling, R; Shi, W; Vredenburgh, JJ; Bigner, DD; Heimberger, AB. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 2011;13:324-333. (2011) Abstract

Adamson, DC; Shi, Q; Wortham, M; Northcott, PA; Di, C; Duncan, CG; Li, J; McLendon, RE; Bigner, DD; Taylor, MD; Yan, H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Research. 2010;70:181-191. (2010) Abstract

Cao, Y; Lathia, JD; Eyler, CE; Wu, Q; Li, Z; Wang, H; McLendon, RE; Hjelmeland, AB; Rich, JN. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes and Cancer. 2010;1:50-61. (2010) Abstract

Hjelmeland, AB; Wu, Q; Wickman, S; Eyler, C; Heddleston, J; Shi, Q; Lathia, JD; Macswords, J; Lee, J; McLendon, RE; Rich, JN. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biology. 2010;8:e1000319. (2010) Abstract

Kuan, CT; Wakiya, K; Herndon, JE; Lipp, ES; Pegram, CN; Riggins, GJ; Rasheed, A; Szafranski, SE; McLendon, RE; Wikstrand, CJ; Bigner, DD. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer. 2010;10:468. (2010) Abstract

Lathia, JD; Gallagher, J; Heddleston, JM; Wang, J; Eyler, CE; Macswords, J; Wu, Q; Vasanji, A; McLendon, RE; Hjelmeland, AB; Rich, JN. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010;6:421-432. (2010) Abstract

Lopez, GY; Reitman, ZJ; Solomon, D; Waldman, T; Bigner, DD; McLendon, RE; Rosenberg, SA; Samuels, Y; Yan, H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications. 2010;398:585-587. (2010) Abstract

Sampson, JH; Heimberger, AB; Archer, GE; Aldape, KD; Friedman, AH; Friedman, HS; Gilbert, MR; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sawaya, R; Schmittling, RJ; Shi, W; Vredenburgh, JJ; Bigner, DD. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology. 2010;28:4722-4729. (2010) Abstract

Sathornsumetee, S; Desjardins, A; Vredenburgh, JJ; McLendon, RE; Marcello, J; Herndon, JE; Mathe, A; Hamilton, M; Rich, JN; Norfleet, JA; Gururangan, S; Friedman, HS; Reardon, DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 2010;12:1300-1310. (2010) Abstract

Boskovitz, A; McLendon, RE; Okamura, T; Sampson, JH; Bigner, DD; Zalutsky, MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nuclear Medicine and Biology. 2009;36:659-669. (2009) Abstract

Heddleston, JM; Li, Z; McLendon, RE; Hjelmeland, AB; Rich, JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8:3274-3284. (2009) Abstract

Horbinski, C; Dacic, S; McLendon, RE; Cieply, K; Datto, M; Brat, DJ; Chu, CT. Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathology. 2009;19:439-448. (2009) Abstract

Lu, Z; Zhou, L; Killela, P; Rasheed, AB; Di, C; Poe, WE; McLendon, RE; Bigner, DD; Nicchitta, C; Yan, H. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Research. 2009;69:9105-9111. (2009) Abstract

Brat, DJ; Parisi, JE; Kleinschmidt-DeMasters, BK; Yachnis, AT; Montine, TJ; Boyer, PJ; Powell, SZ; Prayson, RA; McLendon, RE; Neuropathology Committee, College of American Pathologists. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Archives of Pathology and Laboratory Medicine. 2008;132:993-1007. (2008) Abstract

Parisi, JE; Miller, DV; Boyer, PJ; Brat, DJ; Cochran, EJ; Cohen, ML; Demasters, BK; Dolinak, D; McComb, RD; McLendon, RE; Powell, SZ; Prayson, RA; Vinters, HV; Yachnis, AT; Members of Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with tumors of the brain/spinal cord. Archives of Pathology and Laboratory Medicine. 2008;132:907-912. (2008) Abstract

Zalutsky, MR; Reardon, DA; Akabani, G; Coleman, RE; Friedman, AH; Friedman, HS; McLendon, RE; Wong, TZ; Bigner, DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine. 2008;49:30-38. (2008) Abstract

Grunkemeier, MN; Turner, K; McLendon, RE. Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR. Acta Neuropathologica. 2007;113:217-219. (2007) Abstract

McLendon, RE; Turner, K; Perkinson, K; Rich, J. Second messenger systems in human gliomas. Archives of Pathology and Laboratory Medicine. 2007;131:1585-1590. (2007) Abstract

Bao, S; Wu, Q; McLendon, RE; Hao, Y; Shi, Q; Hjelmeland, AB; Dewhirst, MW; Bigner, DD; Rich, JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760. (2006) Abstract

Maxwell, JA; Johnson, SP; Quinn, JA; McLendon, RE; Ali-Osman, F; Friedman, AH; Herndon, JE; Bierau, K; Bigley, J; Bigner, DD; Friedman, HS. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Molecular Cancer Therapeutics. 2006;5:2531-2539. (2006) Abstract